Stocktwits Tlsa3 Dec 2021 10:15
Saw below message from Stoktwits
$TLSA
On December 11th, Precision Bio will be giving an update of their CAR T portfolio at the ASH annual meeting. Remember, they have a license agreement signed with us for Foralumab to induce tolerance, and therefore clinical outcome, of their CAR T therapy. Hopefully we'll hear about a new clinical trial.
I think we're also expecting news with the last few weeks of this year about an IND submission for TZLS-501 lung disease treatment. Don't sell yet, good things to come!
Oh, from those UK holders, we are not able to sell yet. Come on, GC & KR, we do deserve a Xmas present from you guys!